DrugPatentWatch Database Preview
QUARTETTE Drug Profile
When do Quartette patents expire, and when can generic versions of Quartette launch?
Quartette is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-four patent family members in thirteen countries.
The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for QUARTETTE
| International Patents: | 24 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 2 |
| Patent Applications: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for QUARTETTE |
| Drug Sales Revenues: | Drug sales revenues for QUARTETTE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for QUARTETTE |
| DailyMed Link: | QUARTETTE at DailyMed |
Recent Litigation for QUARTETTE
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Teva Women's Health, Inc. v. Famy Care Ltd. | 2014-12-05 |
| Teva Women's Health, Inc. v. Famy Care Ltd. | 2014-07-02 |
Synonyms for QUARTETTE
| 110541-57-6 |
| 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-, mixt. with (17-alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol |
| 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-(+-)-, mixt. with (17-alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol |
| 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-(+-)-,mixt. with (17-alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol |
| 37263-36-8 |
| 39366-37-5 |
| 52232-43-6 |
| 55927-62-3 |
| 70208-30-9 |
| 8056-51-7 |
| 8063-84-1 |
| 8064-50-4 |
| AC1L2NM9 |
| Adepal |
| AG 200-15 |
| AG200-15 |
| aless |
| Alesse 28 |
| Altavera |
| Anna |
| Anteovin |
| aviane |
| AVIANE-21 |
| Aviane-21Fe |
| AVIANE-28 |
| Biphasil |
| Biphasil 21 |
| Biphasil 28 |
| C21H28O2.C20H24O2 |
| CCRIS 7261 |
| CRYSELLE |
| dl-Norgestrel mixed with ethinylestradiol |
| DTXSID90192569 |
| Duoluton |
| Ediwal |
| Elifemme |
| ENPRESSE-21 |
| ENPRESSE-28 |
| Ethinyl estradiol mixed with norgestrel |
| Ethinyl estradiol mixture with levonorgestrel |
| Ethinyl estradiol mixture with norgestrel |
| ETHINYL ESTRADIOL-NORGESTREL COMBINATION |
| ethinyl estradiol, levonorgestrel drug combination |
| Ethinyl estradiol/levonorgestrel |
| Ethinylestradiol - levonorgestrel mixt |
| Ethinylestradiol - levonorgestrel mixt. |
| Ethinylestradiol mixed with dl-norgestrel |
| Ethinylestradiol mixture with Levonorgestrel |
| Ethinyloestradiol mixed with norgestrel |
| Eugynon |
| Eugynon 30 |
| Femenal |
| Follimin |
| Follinett |
| Follinyl |
| Gravistat |
| Gynatrol |
| Introvale |
| Jolessa |
| LESSINA-21 |
| LESSINA-28 |
| LEVLITE |
| Levonest |
| Levonorgestrel - ethynylestradiol mixt |
| Levonorgestrel - ethynylestradiol mixt. |
| Levonorgestrel and Ethinyl Estradiol |
| Levonorgestrel and Ethinyl Estradiol tablets |
| Levonorgestrel-ethinyl estradiol mixt |
| Levonorgestrel-ethinyl estradiol mixt. |
| Levonorgestrel, ethinyl estradiol |
| Levonorgestrel/ethinyl estradiol |
| Levora |
| LEVORA 0.15/30-21 |
| LEVORA 0.15/30-28 |
| Lo-Femenal |
| LO/OVRAL-28 |
| LOC 31 |
| LOC 31A |
| Logynon |
| Loseasonique |
| Low-ogestrel |
| LOW-OGESTREL-21 |
| LOW-OGESTREL-28 |
| LS-62088 |
| LS-62092 |
| Lybrel |
| Marlissa |
| Microgynon |
| Microgynon 30 |
| Microvlar 30 |
| Minidril |
| Minigynon |
| Minisiston |
| Neogynon |
| Neovlar |
| Neovletta |
| NORDETTE-21 |
| NORDETTE-28 |
| Nordiol |
| Nordiol-28 |
| Norgestrel and Ethinyl Estradiol |
| Norgestrel mixed with ethinyl estradiol |
| Norgestrel mixed with ethinyloestradiol |
| Norgestrel-ethinyl estradiol |
| Norgestrel-Ethinyl Estradiol Combination |
| Norgestrel-ethynylestradiol mixt |
| Norgestrel-ethynylestradiol mixt. |
| OGESTREL 0.5/50-21 |
| OGESTREL 0.5/50-28 |
| Orasecron |
| Ovidon |
| Ovral 21 |
| Ovral 28 |
| Ovral L |
| OVRAL-28 |
| Ovran |
| Ovranett |
| PC 4 (contraceptive) |
| Pearl Oral Contraceptive |
| Portia |
| PORTIA-21 |
| PORTIA-28 |
| PREVEN EMERGENCY CONTRACEPTIVE KIT |
| Primovlar |
| Pro-Duosterone |
| Quasense |
| Rigevidon |
| SCHEMBL4451192 |
| Schering PC 4 |
| Sequilar |
| Sequilarum |
| Sequostat |
| SH 71121 |
| SH D00264A |
| SHB 261AB |
| SHB 264AB |
| Sronyx |
| Stederil 30 |
| Stediril |
| Stediril D |
| Tri-Regol |
| Trigynon |
| Trikvilar |
| Trinordiol |
| Triphasil-21 |
| TRIPHASIL-28 |
| Triquilar |
| Trisiston |
| Trisistone R |
| Trisistone-R |
| TRIVORA-21 |
| TRIVORA-28 |
| Twirla |
| Vienva |
| WL 33 |
| WY-E 104 |
Paragraph IV (Patent) Challenges for QUARTETTE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| QUARTETTE | TABLET;ORAL | ethinyl estradiol; levonorgestrel | 204061 | 2013-07-10 |
US Patents and Regulatory Information for QUARTETTE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | QUARTETTE | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 204061-001 | Mar 28, 2013 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Teva Branded Pharm | QUARTETTE | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 204061-001 | Mar 28, 2013 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QUARTETTE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2009120528 | Start Trial |
| Taiwan | 200831107 | Start Trial |
| Brazil | PI0716291 | Start Trial |
| Mexico | 2009004616 | Start Trial |
| Israel | 182287 | Start Trial |
| South Korea | 20090094437 | Start Trial |
| Israel | 198441 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for QUARTETTE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 122015000093 | Germany | Start Trial | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 |
| 1214076 | C01214076/01 | Switzerland | Start Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 1453521 | CA 2016 00016 | Denmark | Start Trial | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 |
| 1380301 | 2009C/007 | Belgium | Start Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| 0771217 | CA 2006 00038 | Denmark | Start Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804 |
| 0398460 | C300221 | Netherlands | Start Trial | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
| 1453521 | 93156 | Luxembourg | Start Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
